Evidence map›Paper›PMID 27928010›Full record

ArticleJournal of virology2017

Structural Insights into Reovirus σ1 Interactions with Two Neutralizing Antibodies.

Melanie H Dietrich, Kristen M Ogden, Sarah P Katen, Kerstin Reiss, Danica M Sutherland, Robert H Carnahan, Matthew Goff, Tracy Cooper, Terence S Dermody, Thilo Stehle

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Detection of Salmonid IgM Specific to theFrontiers in immunology · 2019
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. The Orchestra of Reovirus Cell Entry.Current clinical microbiology reports · 2017
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Melanie H DietrichInterfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany.
Kristen M OgdenDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Sarah P KatenElizabeth B. Lamb Center for Pediatric Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kerstin ReissInterfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany.
Danica M SutherlandElizabeth B. Lamb Center for Pediatric Research, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Robert H CarnahanVanderbilt Antibody and Protein Resource, Vanderbilt Institute for Chemical Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Matthew GoffVanderbilt Antibody and Protein Resource, Vanderbilt Institute for Chemical Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Tracy CooperVanderbilt Antibody and Protein Resource, Vanderbilt Institute for Chemical Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Terence S DermodyDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA terence.dermody@chp.edu thilo.stehle@uni-tuebingen.de.
Thilo StehleInterfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany terence.dermody@chp.edu thilo.stehle@uni-tuebingen.de.
Vanderbilt University Medical Center · USUniversity of Tübingen · DEVanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Childhood Infections Research ProgramT32AI095202 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JAMES E CASSAT · 2011 to 2026
$4.2M
MOLECULAR PARASITOLOGY TRAINING PROGRAMT32AI007281 · NIAID · MEHARRY MEDICAL COLLEGE · PI NDE, PIUS N · 1985 to 2025
$3.2M
Reovirus Attachment MechanismsR01AI118887 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DERMODY, TERENCE S. · 2015 to 2019
$2.3M
NCI NIH HHS P30 CA068485NIAID NIH HHS R01 AI118887NIAID NIH HHS T32 AI007281NIAID NIH HHS T32 AI095202
6 · The paper itself

Abstract

Reovirus attachment protein σ1 engages glycan receptors and junctional adhesion molecule-A (JAM-A) and is thought to undergo a conformational change during the proteolytic disassembly of virions to infectious subvirion particles (ISVPs) that accompanies cell entry. The σ1 protein is also the primary target of neutralizing antibodies. Here, we present a structural and functional characterization of two neutralizing antibodies that target σ1 of serotype 1 (T1) and serotype 3 (T3) reoviruses. The crystal structures revealed that each antibody engages its cognate σ1 protein within the head domain via epitopes distinct from the JAM-A-binding site. Surface plasmon resonance and cell-binding assays indicated that both antibodies likely interfere with JAM-A engagement by steric hindrance. To define the interplay between the carbohydrate receptor and antibody binding, we conducted hemagglutination inhibition assays using virions and ISVPs. The glycan-binding site of T1 σ1 is located in the head domain and is partly occluded by the bound Fab in the crystal structure. The T1-specific antibody inhibited hemagglutination by virions and ISVPs, probably via direct interference with glycan engagement. In contrast to T1 σ1, the carbohydrate-binding site of T3 σ1 is located in the tail domain, distal to the antibody epitope. The T3-specific antibody inhibited hemagglutination by T3 virions but not ISVPs, indicating that the antibody- and glycan-binding sites in σ1 are in closer spatial proximity on virions than on ISVPs. Our results provide direct evidence for a structural rearrangement of σ1 during virion-to-ISVP conversion and contribute new information about the mechanisms of antibody-mediated neutralization of reovirus. IMPORTANCE: Virus attachment proteins mediate binding to host cell receptors, serve critical functions in cell and tissue tropism, and are often targeted by the neutralizing antibody response. The structural investigation of antibody-antigen complexes can provide valuable information for understanding the molecular basis of virus neutralization. Studies with enveloped viruses, such as HIV and influenza virus, have helped to define sites of vulnerability and guide vaccination strategies. By comparison, less is known about antibody binding to nonenveloped viruses. Here, we structurally investigated two neutralizing antibodies that bind the attachment protein σ1 of reovirus. Furthermore, we characterized the neutralization efficiency, the binding affinity for σ1, and the effect of the antibodies on reovirus receptor engagement. Our analysis defines reovirus interactions with two neutralizing antibodies, allows us to propose a mechanism by which they block virus infection, and provides evidence for a conformational change in the σ1 protein during viral cell entry.

Indexed as

ReoviridaeAmino Acid SequenceAnimalsAntibodies, NeutralizingAntibodies, ViralBinding SitesCell LineCHO CellsCricetulusHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin Fab FragmentsMiceMolecular Docking SimulationMolecular Dynamics SimulationNeutralization TestsProtein BindingAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin Fab FragmentsViral Proteinscrystal structureFab fragmentsflow cytometryimmune escapemammalian reovirusesmonoclonal antibodiesquaternary binding epitopereceptor bindingsurface plasmon resonancevirus neutralization

Identifiers

PMID27928010
PMCPMC5286903
OpenAlexW2560832589

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.